Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) - TA4

The Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office (BTO) is seeking support for the commercialization of technologies developed under the Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) program. This special notice, identified as DARPA-SN-26-91, serves to notify the community of specific program goals, initiate dialogue regarding technical needs, and establish the timetable for full proposal submissions. The effort is conducted under the DARPA BTO Office Wide Broad Agency Announcement HR001126S0003, titled “Biological Technologies.”

The primary point of contact for this initiative is LCDR Robert Murray, Program Manager. The opportunity is classified under NAICS 541714: Research and Development in Biotechnology (except Nanobiotechnology) and PSC AC12: NATIONAL DEFENSE R&D SERVICES; DEPARTMENT OF DEFENSE - MILITARY; APPLIED RESEARCH. Detailed information regarding the program’s objectives is contained in a single PDF attachment titled DARPA-SN-26-91.pdf, which was published on June 11, 2026.

Interested parties must submit responses by the deadline of June 29, 2026. The requirement is issued by the Departmental Offices and does not specify a set-aside or a designated place of performance within the notice metadata. All activities and submissions are governed by the overarching BAA framework provided by DARPA.